On Dec. 29, 2022, China National Medical Products Administration (NMPA) conditionally approved Merck Sharp & Dohme (MSD)’s Molnupiravir Capsules (brand name: Lagevrio) for COVID-19 treatment.
The antiviral small-molecule drug is approved for treating patients who have mild-to-moderate COVID-19 infections and high risks to develop into severe conditions. The risks can be advanced age, obesity or overweightness, chronic kidney disease, diabetes, severe cardiovascular disease, chronic obstructive pulmonary disease (COPD), active cancer, etc.
MSD has authorized Sinopharm Group with the exclusive right to import and sell Lagevrio in the mainland Chinese market.
Lagevrio’s price in China has not been revealed. In the US, one course costs 700 USD (circa 4,818 yuan).
By Jan. 31, 2023, China NMPA has approved six COVID-19 treatments:
Marketing Authorization Holder
Price for One Course
Within Basic Insurance
Without Basic Insurance
Romlusevimab Combination Therapy (BRII-196/BRII-198)
Dec. 8, 2021
Brii Biosciences revealed the price scope: ≤ 10,000 yuan
Nirmatrelvir Tablets and Ritonavir Tablets (Paxlovid)
Feb 11, 2022
1,890 yuan until Mar. 31, 2023
July 25, 2022
Molnupiravir Capsules (Lagevrio)
Dec. 29, 2022
Simnotrelvir Tablets / Ritonavir Tablets (Xian Nuo Xin)
Jan. 29, 2023
Shanghai Vinnerna Biosciences (joint venture of Junshi Biosciences and Suzhou Wangshan Wangshui Biomedicine)
Jan. 29, 2023
Updated on Jan. 31, 2023